AMPHASTAR PHARMACEUTICALS IN (AMPH)

US03209R1032 - Common Stock

40.45  +0.67 (+1.68%)

After market: 40.45 0 (0%)

Fundamental Rating

6

AMPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make AMPH suitable for value investing!



9

1. Profitability

1.1 Basic Checks

AMPH had positive earnings in the past year.
AMPH had a positive operating cash flow in the past year.
AMPH had positive earnings in each of the past 5 years.
AMPH had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

AMPH's Return On Assets of 9.82% is amongst the best of the industry. AMPH outperforms 93.26% of its industry peers.
AMPH's Return On Equity of 23.00% is amongst the best of the industry. AMPH outperforms 92.23% of its industry peers.
AMPH has a Return On Invested Capital of 12.93%. This is amongst the best in the industry. AMPH outperforms 92.23% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is significantly below the industry average of 17.70%.
The last Return On Invested Capital (12.93%) for AMPH is above the 3 year average (11.94%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.82%
ROE 23%
ROIC 12.93%
ROA(3y)10.22%
ROA(5y)7.84%
ROE(3y)17.58%
ROE(5y)13.18%
ROIC(3y)11.94%
ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 22.87%, AMPH belongs to the top of the industry, outperforming 94.30% of the companies in the same industry.
AMPH's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 31.29%, AMPH belongs to the top of the industry, outperforming 94.82% of the companies in the same industry.
AMPH's Operating Margin has improved in the last couple of years.
The Gross Margin of AMPH (54.32%) is better than 63.21% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 31.29%
PM (TTM) 22.87%
GM 54.32%
OM growth 3Y114.39%
OM growth 5YN/A
PM growth 3Y276.41%
PM growth 5YN/A
GM growth 3Y10.26%
GM growth 5Y8.62%

5

2. Health

2.1 Basic Checks

AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AMPH has about the same amout of shares outstanding than it did 1 year ago.
AMPH has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AMPH has a worse debt to assets ratio.

2.2 Solvency

AMPH has an Altman-Z score of 2.80. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.80, AMPH is in the better half of the industry, outperforming 75.13% of the companies in the same industry.
AMPH has a debt to FCF ratio of 3.69. This is a good value and a sign of high solvency as AMPH would need 3.69 years to pay back of all of its debts.
The Debt to FCF ratio of AMPH (3.69) is better than 87.56% of its industry peers.
A Debt/Equity ratio of 0.88 indicates that AMPH is somewhat dependend on debt financing.
AMPH has a Debt to Equity ratio of 0.88. This is in the lower half of the industry: AMPH underperforms 69.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 3.69
Altman-Z 2.8
ROIC/WACC1.52
WACC8.51%

2.3 Liquidity

A Current Ratio of 2.18 indicates that AMPH has no problem at all paying its short term obligations.
The Current ratio of AMPH (2.18) is worse than 63.21% of its industry peers.
A Quick Ratio of 1.72 indicates that AMPH should not have too much problems paying its short term obligations.
AMPH's Quick ratio of 1.72 is on the low side compared to the rest of the industry. AMPH is outperformed by 66.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.18
Quick Ratio 1.72

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 75.47% over the past year.
Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 70.36% on average per year.
AMPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.40%.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.94% yearly.
EPS 1Y (TTM)75.47%
EPS 3Y72.76%
EPS 5Y70.36%
EPS Q2Q%67.74%
Revenue 1Y (TTM)30.4%
Revenue growth 3Y22.59%
Revenue growth 5Y16.94%
Sales Q2Q%22.72%

3.2 Future

Based on estimates for the next years, AMPH will show a decrease in Earnings Per Share. The EPS will decrease by -4.87% on average per year.
The Revenue is expected to grow by 1.16% on average over the next years.
EPS Next Y17.3%
EPS Next 2Y16.31%
EPS Next 3Y16.21%
EPS Next 5Y-4.87%
Revenue Next Year17.19%
Revenue Next 2Y11.5%
Revenue Next 3Y10.69%
Revenue Next 5Y1.16%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 10.87, the valuation of AMPH can be described as very reasonable.
90.16% of the companies in the same industry are more expensive than AMPH, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 28.63. AMPH is valued rather cheaply when compared to this.
AMPH is valuated reasonably with a Price/Forward Earnings ratio of 9.06.
AMPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 90.16% of the companies in the same industry.
AMPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 20.22.
Industry RankSector Rank
PE 10.87
Fwd PE 9.06

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaper than 90.16% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 89.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.29
EV/EBITDA 8.44

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
AMPH's earnings are expected to grow with 16.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.63
PEG (5Y)0.15
EPS Next 2Y16.31%
EPS Next 3Y16.21%

0

5. Dividend

5.1 Amount

No dividends for AMPH!.
Industry RankSector Rank
Dividend Yield N/A

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (6/21/2024, 7:00:00 PM)

After market: 40.45 0 (0%)

40.45

+0.67 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.98B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 10.87
Fwd PE 9.06
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.63
PEG (5Y)0.15
Profitability
Industry RankSector Rank
ROA 9.82%
ROE 23%
ROCE
ROIC
ROICexc
ROICexgc
OM 31.29%
PM (TTM) 22.87%
GM 54.32%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.18
Quick Ratio 1.72
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)75.47%
EPS 3Y72.76%
EPS 5Y
EPS Q2Q%
EPS Next Y17.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)30.4%
Revenue growth 3Y22.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y